Skip to main content
Equibles
ANAB logo

ANAB · Anaptysbio, Inc · Metrics

Track ANAB — free

Use ANAB with AI

Add company filings, earnings and prices to ChatGPT or Claude, then ask questions in your own chat.

Choose your app for step-by-step connection instructions. Sign in with Equibles when asked; no code or API key is needed.

Claude ChatGPT

After connecting, ask your AI to use Equibles to research ANAB.

Other apps & server URL
https://mcp.equibles.com/mcp
Gemini CLI setup
or ask here

Free, nothing to set up — ALVIS runs on the same tools and cites every figure.

See what you can ask in ChatGPT or Claude

All connection guides →
$48.73 +0.63 (+1.31%) At close · Oct 23
Russell 2000 member Rebalance outlook locked
Market Cap
$1.42B
Shares
29.10M
Volume · Oct 23 468.21K Avg daily vol (3M) 503.05K

ANAB metrics

66 of 122 screener metrics currently available.

Open in screener

Market overview

2 metrics
Share price
$48.73
Market cap
$1.42B

Price action

20 metrics
Price change (1W)
+4.5%
Price change (30D)
-4.5%
Price change (3M)
-10.0%
Price change (6M)
-17.2%
Price change (YTD)
—
Price change (1Y)
—
Trailing year
Price change (5Y)
—
52-week high
—
52-week low
—
Change from 52-week high
—
Change from 52-week low
—
Annualized volatility
61.7%
Annualized volatility (3M)
41.7%
Beta
0.9
RSI (14D)
48.3
Price vs SMA 50
-7.5%
Price vs SMA 200
—
Avg volume (3M)
503,048
Relative volume
0.9
Average dollar volume
$26.50M

Company

3 metrics
Sector
Healthcare
Industry
Biotechnology
Shares outstanding
29.10M

Valuation

12 metrics
P / E (TTM)
—
Trailing earnings
PEG ratio
—
EV / revenue
—
EV / EBITDA
—
EV / EBIT
—
P / sales
6.1×
reciprocal yield 16.4%
P / book
111.2
reciprocal yield 0.9%
FCF yield
0.3%
TTM · current market cap
Buyback yield
4.5%
P / FCF
321.6
reciprocal yield 0.3%
P / operating cash flow
316.7
reciprocal yield 0.3%
Earnings yield
-1.9%

Historical valuation

8 metrics
P / E historical average (3Y)
—
P / E historical average (5Y)
—
EV / revenue historical average (3Y)
—
EV / revenue historical average (5Y)
—
EV / EBIT historical average (3Y)
—
EV / EBIT historical average (5Y)
—
EV / EBITDA historical average (3Y)
—
EV / EBITDA historical average (5Y)
—

Dividends & buybacks

7 metrics
Dividend yield
—
Trailing 12 months
Payout ratio
—
Shareholder yield
4.5%
Dividend / share (TTM)
—
Dividend growth YoY
—
Dividend growth streak
—
Last ex-dividend
—

Earnings calendar

2 metrics
Next earnings
—
Last earnings
2026-05-12

Profitability

9 metrics
Gross margin
—
Operating margin
17.6%
Trailing 12 months
Net margin
-11.5%
Gross profit (TTM)
—
Operating profit (TTM)
$40.80M
Net income (TTM)
−$26.79M
Trailing 12 months
Diluted EPS (TTM)
$-0.87
FCF margin
1.9%
Effective tax rate
—

Per share

11 metrics
Revenue per diluted share (TTM)
—
Gross profit per diluted share (TTM)
—
Operating profit per diluted share (TTM)
—
EBITDA per diluted share (TTM)
—
Net income per diluted share (TTM)
—
Operating cash flow per diluted share (TTM)
—
Free cash flow per diluted share (TTM)
—
Capital expenditures per diluted share (TTM)
—
R&D per diluted share (TTM)
—
Stock compensation per diluted share (TTM)
—
Book value per share
$1.33

Growth

11 metrics
Revenue growth YoY
-8.0%
Year over year
Net income growth YoY
—
Revenue (TTM)
$232.39M
Trailing 12 months
EPS growth YoY
—
Shares change YoY
-6.4%
Year over year · fewer shares
Revenue CAGR (3Y)
+183.6%
Revenue CAGR (5Y)
+25.6%
EPS CAGR (3Y)
—
EPS CAGR (5Y)
—
FCF CAGR (3Y)
—
FCF CAGR (5Y)
—

Quality

14 metrics
Return on equity
-210.1%
Return on assets
-8.1%
Debt / equity
—
Current ratio
7.6
EBITDA (TTM)
$41.34M
Free cash flow (TTM)
$4.41M
Quick ratio
7.6
Interest coverage
—
Net debt / EBITDA
-6.0
Return on invested capital
—
Trailing 12 months
Net cash
$248.47M
Latest balance sheet
Cash & equivalents
$248.47M
Total assets
$329.68M
Total debt
—

Cash flow & spend

7 metrics
Operating cash flow (TTM)
$4.48M
Capital expenditures (TTM)
$69,000
R&D (TTM)
$128.78M
SG&A (TTM)
—
Stock compensation (TTM)
$41.12M
R&D / revenue
55.4%
Stock compensation / revenue
17.7%

Ownership (13F)

9 metrics
13F filers
215
13F filer change QoQ
+7
Institutional ownership
104.0%
Conviction holders (share of 13F filers)
3.3%
Crowding (high-turnover and private-fund holders)
—
Private-fund adviser ownership
—
Active holders' share change QoQ
-28.8%
Holder tenure
16.7
Price vs estimated holder cost
+216.9%

Ownership (registered funds)

1 metrics
Index-fund ownership
14.2%

Short interest

3 metrics
Short interest
18.0%
Latest settlement · 8.2 days to cover
Days to cover
8.2d
Short-squeeze score
63 / 100

Insider activity

2 metrics
Net insider buying (90D)
−$249,372
Insider-sentiment score
—

Risk flags

1 metrics
Going concern
—
Key facts CIK 1370053 CUSIP 032724106 13F (30d) 19 filings 19 filers Visit website Investor relations